LinkedIn Corporation LNKD: NYSE; Technology/IT Services & Consulting

LinkedIn Corporation

LNKD: NYSE; Technology/IT Services & Consulting

PRIMARY EXCHANGE: NYSE   OTHER EXCHANGES: Mexico, SIX Swiss Exchange, More »

 

LAST	CHANGE	VOLUME
At close 03/12/2015	$266.42	+1.47 +0.55%	944.1K
AFTER HOURS 5:27 PM ET	$266.42	0.00 0.00%

 

News about LinkedIn Corporation, including commentary and archival articles published in The New York Times.

Company Information

LinkedIn Corporation (LinkedIn), is a professional network on the Internet with approximately 277 million members in over 200 countries and territories. Its Free Solutions includes ability to manage professional identity, ability to build and engage with professional networks, access to knowledge, insights and opportunities and ubiquitous access. 

 

 

 

 

The Company generates revenue across three product lines: Talent Solutions, Marketing Solutions, and Premium Subscriptions. All three product lines are sold through two channels, an offline field sales organization, which engages with both large and small enterprise customers, as well as an online, self-serve channel where it generates revenue from both enterprise customers and individual members purchasing subscriptions. On February 28, 2014, it acquired the entire share capital of Bright Media Corporation (Bright). In July 2014, it acquired Newsle Inc. In August 2014, LinkedIn Corp. acquired Bizo, Inc.

 

LinkedIn Corporation
2029 Stierlin Ct MOUNTAIN VIEW CA 94043-4655
Phone: +1 (650) 687-3600
Fax: +1 (302) 636-5454

Price Chart

1 day | 5 day | 3 month | 1 year | 5 year

Data delayed at least 15 minutes

View historical chart »

Stock Snapshot

Today's open	$265.70
Wednesday's close	$264.95
52-week range
52-week high	$276.18
52-week low	$136.02
Market capitalization	33.4B
Avg. volume (10-day)	1.1M
Shares outstanding	125.1M
LNKD does not pay dividends

Key Fundamentals

P/E ratio	n.a.
Earnings per share	–$0.13
Revenue	$2.2B
Profit margin	–0.69%
Return on equity	–0.53%

Fundamentals are for the trailing 12 months

View financials »

Quarterly Earnings

Analyst Ratings

Buy	13
Outperform	17
Hold	11
Underperform	0
Sell	0
Consensus		Outperform

(As of 03/07/2015)

Executive Officers

Executive	Title
Reid G. Hoffman	Chmn. since 2003
Jeffrey Weiner	CEO since 2009
Steven J. Sordello	CFO since 2007
Michael Gamson	Sr.VP
J. Kevin Scott	Sr.VP since 2012

Latest Insider Trades

03/02/2015

SZE DAVID

Open market or private sale of non-derivative or derivative security

Shares sold:	300
Share price:	$266.30
Trans. value:	$79,890

03/02/2015

SZE DAVID

Open market or private sale of non-derivative or derivative security

Shares sold:	513
Share price:	$267.46
Trans. value:	$137,207

03/02/2015

SZE DAVID

Open market or private sale of non-derivative or derivative security

Shares sold:	587
Share price:	$268.37
Trans. value:	$157,533

Company Events

• On February 5, 2015, LNKD announced quarterly earnings of $0.61 per share for 2014Q4, beating the consensus estimate of $0.53.

Filings

10-K

Annual Financials

February 12, 2015

10-Q

Quarterly Financials

October 30, 2014

10-Q

Quarterly Financials

July 31, 2014

Ownership Submissions

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: January 31, 2005 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Gamson Michael   2. Issuer Name and Ticker or Trading Symbol LINKEDIN CORP [LNKD] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) SVP, Global Solutions (Last) (First) (Middle) C/O LINKEDIN CORPORATION, 2029 STIERLIN COURT 3. Date of Earliest Transaction (Month/Day/Year) 02/27/2015 (Street) MOUNTAIN VIEW, CA 94043 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) _X_ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Class A Common Stock 02/27/2015   A   17,521(1) A $ 0 51,061 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Employee Stock Option (Right to Buy)

$267.2

02/27/2015

A

15,018

(2)

03/01/2025

Class A Common Stock

15,018

$ 0

15,018

D

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Gamson Michael C/O LINKEDIN CORPORATION 2029 STIERLIN COURT MOUNTAIN VIEW, CA 94043			SVP, Global Solutions

Signatures

/s/ Lora D. Blum, as Attorney-In-Fact		03/03/2015
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The reported shares are represented by restricted stock units ("RSUs"). The RSUs vest six and one-quarter percent (6.25%) on May 15, 2015, and six and one-quarter percent (6.25%) of the RSUs will vest on each subsequent Company Vest Date until all of the grant is vested. "Company Vest Dates" are defined as February 15, May 15, August 15 and November 15 of each year (to the extent that any of the Company Vest Dates fall on a weekend or Company holiday, that Company Vest Date will be the first business day following the relevant Company Vest Date).
(2)	Shares subject to the option vest in 48 equal monthly installments beginning on March 1, 2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

5 Strong Buy Healthcare Funds to Bet on

When markets are passing through choppy waters, investors often rely on the healthcare sector to safeguard their investments. This is because the demand for healthcare services does not vary with market conditions, making them a safe haven during difficult times. Many pharmacy companies also generate regular dividends, which go a long way in softening the blow dealt by plummeting share prices. Mutual funds are the perfect choice for investors looking to enter this sector since they possess the advantages of wide diversification and analytical insight.

Below we will share with you 5 top rated health mutual funds. Each has earned a Zacks #1 Rank (Strong Buy) as we expect these mutual funds to outperform their peers in the future. To view the Zacks Rank and past performance of all health funds, investors can click here to see the complete list of funds.

Fidelity Select Medical Delivery Portfolio (FSHCX - MF report) invests largely in companies that own or are involved in operating hospital and nursing homes, and are related to health care services sector. The fund focuses on acquiring common stocks of both U.S. and non U.S. companies. This healthcare mutual fund is non-diversified and returned 26.3% over the last one year period.

The fund has an expense ratio of 0.82% as compared to category average of 1.39%.

Vanguard Health Care Index Admiral (VHCIX - MF report) seeks to provide returns identical to that of the MSCI US Investable Market Index (IMI)/Health Care 25/50 index. The fund invests in almost all or all of the stocks which are included in the index. The index includes domestic health care companies. This healthcare mutual fund is non-diversified and returned 28.3% over the last one year period.

As of July 2014, this fund held 312 issues with 10.14% of its assets invested in Johnson & Johnson.

Fidelity Select Medical Equipment & Systems (FSMEX - MF report) invests a lion’s share of its assets in companies that are primarily involved in medical equipment and devices and related technologies sector. The fund invests in both US and non-US companies. This healthcare mutual fund is non-diversified and returned 27.8% over the last one year period.

Edward Yoon is the fund manager and has managed this healthcare mutual fund since 2007.

Fidelity Select Health Care (FSPHX - MF report) seeks capital growth over the long run. It invests a majority of its assets in companies whose principal operations include production, design and marketing of health care related products or services. The fund focuses on acquiring common stocks and purchases both domestic and foreign securities depending on factors such as financial strength and economic conditions. This non-diversified fund returned 41.3% over the last one year period.

The fund has an expense ratio of 0.76% as compared to category average of 1.39%.

 

Fidelity Select Pharmaceuticals (FPHAX - MF report) invests heavily in firms all over the globe whose primary operations are related to manufacturing, selling, developing or distributing pharmaceuticals and drugs. The fund invests in the pharma sector taking into consideration the industry position and the financial condition of the issuer. This healthcare mutual fund is non-diversified and returned 33.9% over the last one year period.

As of July 2014, this fund held 89 issues with 8.53% of its assets invested in Actavis PLC

To view the Zacks Rank and past performance of all health mutual funds, investors can click here to see the complete list of funds.

About Zacks Mutual Fund Rank

By applying the Zacks Rank to mutual funds, investors can find funds that not only outpaced the market in the past but are also expected to outperform going forward. Learn more about the Zacks Mutual Fund Rank in our Mutual Fund Center.